Cowen analyst Eric Schmidt weighed in on Amgen (NASDAQ: AMGN) after the highly anticipated FOURIER CV outcomes data details were ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Trader Talk

While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman SachsMarch 17, 2017 11:05 AM Baird Incrementally Negative on Amgen (AMGN) Following FOURIER DataMarch 17, 2017 10:40 AM Amgen (AMGN) call put ratio 1 call to 1.26 puts after reporting Repatha data March 17, 2017 9:55 AM Amgen (AMGN) options expected to be active after reporting Repatha data March 17, 2017 9:31 AM Pre-Open Movers 03/17: (GALE) (TIF) (ADBE) Higher; (ESPR) (MDCO) (AMGN) Lower (more...)March 17, 2017 9:28 AM Medicines Co. (MDCO), Esperion Therapeutics (ESPR) Plunge Following Amgen's (AMGN) Repatha DataMarch 17, 2017 9:04 AM Amgen (AMGN) Says Outcomes Study Shows Repatha Decreases LDL-C to Unprecedented Low Levels, Reduces Risk of Cardiovascular EventsMarch 17, 2017 9:01 AM Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety IssuesMarch 17, 2017 9:00 AM Wall St. flat as banks, Amgen weigh; Adobe ralliesMarch 17, 2017 7:33 AM Amgen (AMGN), Peers on Watch Ahead of Repetha Data at ACC.17 (REGN) (ESPR) (MDCO)March 17, 2017 6:59 AM